20 completed. 20 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 20 |
| Phase 1 | 3 | Completed 3 |
Follow Thyroid Carcinoma, Anaplastic: new trials by email Literature Review of Thyroid Carcinoma, Anaplastic trials Research Report on Thyroid Carcinoma, Anaplastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study Cabozantinib 40 mg - Neuroendocrine Tumor, Anaplastic Thyroid Cancer | Phase 2 | Completed | Grupo Espanol de Tumores Neuroendocrinos | 93 | 2020-10-07 | 2025-06-19 |
| Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer Abemaciclib - Thyroid Cancer, Anaplastic Thyroid Cancer | Phase 2 | Completed | Stanford University | 9 | 2020-09-10 | 2025-06-05 |
| Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer Nexavar, operation, External radiation therapy - Thyroid Cancer, Anaplastic | Phase 2 | Completed | Fujian Medical University | 18 | 2018-05-01 | 2024-04-19 |
| Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer Docetaxel, Doxorubicin Hydrochloride, Intensity-Modulated Radiation Therapy - Thyroid Gland Undifferentiated (Anaplastic) Carcinoma | Phase 2 | Completed | Mayo Clinic | 3 | 2017-08-14 | 2020-03-25 |
| Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer Pembrolizumab - Anaplastic Thyroid Cancer | Phase 2 | Completed | Saad A Khan | 6 | 2016-10-01 | 2022-02-10 |
| Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer Lenvatinib - Anaplastic Thyroid Cancer | Phase 2 | Completed | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 39 | 2016-04-04 | 2020-06-17 |
| A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer MLN0128 - Anaplastic Thyroid Cancer, Thyroid Cancer | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 46 | 2015-07-01 | 2024-01-12 |
| Phase I/II Study of PDR001 in Patients With Advanced Malignancies PDR001 - Melanoma, Non-small Sell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Completed | Novartis Pharmaceuticals | 319 | 2015-04-27 | 2022-08-03 |
| Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer efatutazone, paclitaxel - Anaplastic Thyroid Cancer, Recurrent Thyroid Cancer | Phase 2 | Completed | Alliance for Clinical Trials in Oncology | 19 | 2014-12-30 | 2025-01-27 |
| Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers Dabrafenib, Trametinib - Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 206 | 2014-03-12 | 2023-08-21 |
| A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) Crolibulin, Cisplatin - Solid Tumor, Anaplastic Thyroid Cancer | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 27 | 2011-01-26 | 2017-04-10 |
| Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride - Thyroid Gland Anaplastic Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 123 | 2010-10-28 | 2022-07-19 |
| Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer everolimus, laboratory biomarker analysis - Head and Neck Cancer | Phase 2 | Completed | Yonsei University | 40 | 2010-03-01 | 2014-12-02 |
| Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer Laboratory Biomarker Analysis, Pazopanib Hydrochloride - Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 152 | 2008-02-22 | 2020-02-26 |
| Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer sorafenib - Metastatic Differentiated Thyroid Cancer, Metastatic Poorly Differentiated Thyroid Cancer | Phase 2 | Completed | University of Pennsylvania | 59 | 2006-02-01 | 2019-11-18 |
| Gefitinib in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer That Did Not Respond to Iodine Therapy Gefitinib - Head and Neck Cancer | Phase 2 | Completed | Massachusetts General Hospital | 27 | 2003-03-01 | 2017-05-31 |
| Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer fosbretabulin disodium - Head and Neck Cancer | Phase 2 | Completed | Case Comprehensive Cancer Center | 26 | 2003-02-01 | 2010-06-11 |
| Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer filgrastim, fluorouracil, hydroxyurea - Head and Neck Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 1999-08-01 | 2013-07-10 | |
| Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors aldesleukin, ras peptide cancer vaccine, sargramostim - Colorectal Cancer, Endometrial Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 1997-10-01 | 2013-06-20 | |
| Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors cisplatin, doxorubicin hydrochloride, tamoxifen citrate - Adrenocortical Carcinoma, Brain and Central Nervous System Tumors | Phase 2 | Completed | Ottawa Regional Cancer Centre | 30 | 1994-05-01 | 2013-07-10 |
Thyroid Neoplasms (10) · Carcinoma, Medullary (6) · Head and Neck Neoplasms (6) · Adenocarcinoma, Follicular (4) · Thyroid Cancer, Papillary (4) · Carcinoma, Hepatocellular (2) · Carcinoma, Non-Small-Cell Lung (2) · Glioma (2) · Liver Neoplasms (2) · Melanoma (2) · Pheochromocytoma (2) · Adenocarcinoma (1) · Adrenocortical Carcinoma (1) · Astrocytoma (1)
Carcinoma (20) · Neoplasms by Histologic Type (20) · Neoplasms, Glandular and Epithelial (20) · Neoplasms (19) · Neoplasms by Site (13) · Endocrine Gland Neoplasms (10) · Endocrine System Diseases (10) · Thyroid Diseases (10) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Nerve Tissue (9) · Neuroectodermal Tumors (9) · Neuroendocrine Tumors (7) · Adenocarcinoma (6) · Carcinoma, Neuroendocrine (6) · Neoplasms, Ductal, Lobular, and Medullary (6)
Paclitaxel (3) · Cisplatin (2) · Doxorubicin (2) · Radiotherapy (2) · Radiotherapy, Intensity-Modulated (2) · Sorafenib (2) · pazopanib (2) · pembrolizumab (2) · Docetaxel (1) · Everolimus (1) · Filgrastim (1) · Fluorouracil (1) · Gefitinib (1) · Hydroxyurea (1) · Surgical Procedures, Operative (1)
National Cancer Institute (NCI) (5) · Novartis Pharmaceuticals (2) · Alliance for Clinical Trials in Oncology (1) · Case Comprehensive Cancer Center (1) · Dana-Farber Cancer Institute (1) · Fujian Medical University (1) · Grupo Espanol de Tumores Neuroendocrinos (1) · Massachusetts General Hospital (1) · Mayo Clinic (1) · Ottawa Regional Cancer Centre (1) · Saad A Khan (1) · Stanford University (1) · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (1) · University of Pennsylvania (1) · Yonsei University (1)
United States (15) · Canada (3) · Spain (3) · China (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · Netherlands (2) · Norway (2) · South Korea (2) · Taiwan (2) · Australia (1) · Austria (1) · Belgium (1)
Ashish Chintakuntlawar (1) · Barry L. Gause, MD (1) · Byung Chul Cho (1) · Eric J Sherman (1) · Iwao Sugitani, M.D., Ph.D (1) · James Gulley, M.D. (1) · Jaume Capdevila, M.D, Ph.D (1) · John R Clark, MD (1) · Kartik Seghal, MD (1) · Keith C Bible (1) · Makoto Tahara, M.D., Ph.D (1) · Marcia S Brose, MD PhD (1) · Merrill S. Kies, MD (1) · Panayiotis Savvides, MD (1)
PMID 27240885, PMID 17985985, PMID 19265494, PMID 20851682, PMID 24050953, PMID 25092772, PMID 29072975, PMID 32179633, PMID 32364844, PMID 32538690, PMID 32818466, PMID 34838156, PMID 36108341, PMID 36681089, PMID 37059834, PMID 37219859, PMID 37816266, PMID 37934000
P30CA015083 (2), 2014 (1), 2019 (1), N01CM00099 (1), N01CM62205 (1), P30CA006516 (1), P30CA043703 (1), U10CA021661 (1), U10CA031946 (1), U10CA180821 (1), U10CA180868 (1)